NCD

Prescient Releases Predictive Maintenance Solution Kit with NCD and Wago

Retrieved on: 
Tuesday, April 19, 2022
Computer, CEO, WAGO, DataOps, Automation, LLC, NCD, Linux, CAGR, Foreknowledge, Interconnection, Vibration, Interface, Intel, Software development, Technology, Heart, CAGE, AC, Ashish Yadav, Temperature, Industry, Solution, Communication, Innovation, IOT, Multimedia, RAM, Industrial internet of things, Video game console, Maintenance (technical), Instrumentation, Statista

Developed jointly with National Control Devices (NCD), a top provider of long-range industrial wireless sensors, and WAGO, a leader in interconnect, interface, and automation solutions, the new Prescient Predictive Kit is the most customizable and extensible predictive maintenance solution on the market.

Key Points: 
  • Developed jointly with National Control Devices (NCD), a top provider of long-range industrial wireless sensors, and WAGO, a leader in interconnect, interface, and automation solutions, the new Prescient Predictive Kit is the most customizable and extensible predictive maintenance solution on the market.
  • Prescient, NCD, and WAGO are releasing the industry's first low-code predictive maintenance solution kit.
  • This solution enables customers to customize its predictive maintenance solution without requiring software development expertise.
  • The Prescient Predictive Kit includes an NCD wireless predictive maintenance sensor, a WAGO edge computer, and a low-code predictive maintenance template dataflow inside Prescient's flagship data automation software, Prescient Designer.

Systemic Barriers People with IDD Face; NCD Calls to End Inequity, Increase Medical Training

Retrieved on: 
Monday, April 18, 2022
People, Patient, COVID-19, National Council, Center, Family, Adoption, Behavior, Center for Medicare and Medicaid Innovation, Woman, Population, IDD, Disability in Canada, Cervical cancer, Element, NCD, Parent, Paper, Education, Curriculum, Intellectual, Life expectancy, Student, Breast cancer, Lifespan, Health equity, National Council on Disability, Intellect, Health care, Nursing, American Academy, Physician, Developmental Medicine & Child Neurology, Quality of life, Attention, Risk, COVID, United States Department of Health and Human Services, Centers for Medicare & Medicaid Services, Medicare, School, Health, Institute, Medicine, Health insurance, Medical imaging, Disability, Dentistry

CLEARWATER, Fla., April 18, 2022 /PRNewswire-PRWeb/ --The lack of training for healthcare providers specifically related to treating people with intellectual and developmental disabilities (IDD) has been a matter of discussion for many years. Healthcare workers attending to people with IDD—from the supporter to the clinician—inadvertently have put this population at risk because they lack the necessary training to fully meet their healthcare needs. "Advocates and some physicians have maintained that this compromised ability of the healthcare community to meet the needs of people with IDD is a form of discrimination" says Dr. Craig Escudé, physician and president of IntellectAbility.

Key Points: 
  • The NCD paper addresses the disparities in healthcare treatment for individuals with IDD, including how it is exacerbated by the lack of medical training.
  • The paper highlighted the physical and systemic barriers that stand in the way of sufficient access to healthcare for people with disabilities.
  • The NCD also mentions how the COVID-19 pandemic exposed the discrimination that people with intellectual disabilities experience regarding the medical services they receive.
  • (4) It's a 6-module, online course that teaches the fundamentals of IDD healthcare to both medical students and practicing clinicians.

Compromising Patient Access Is Not a Path Forward for Alzheimer’s Disease

Retrieved on: 
Friday, April 8, 2022
FDA, Public Policy, Government, Clinical Trials, Healthcare Reform, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Risk, Cancer, Partnership, Neutralizing antibody, Conditional sentence, Therapy, Degenerative disease, Caregiver, Color, CMS, Centers for Medicare & Medicaid Services, National coverage determination, Amyloid, Chronic condition, Safety, NCD, Hope, Physician, Center, Medicare, FDA, Patient, Health insurance, Pharmaceutical industry

We have serious concerns about how the NCD severely limits access to an entire category of new treatments for Alzheimers disease and will exacerbate health disparities.

Key Points: 
  • We have serious concerns about how the NCD severely limits access to an entire category of new treatments for Alzheimers disease and will exacerbate health disparities.
  • The unparalleled precedent this weeks decision makes has compounded those concerns across the chronic disease community.
  • We have waited decades for disease-modifying treatments for Alzheimers disease.
  • A thousand people a day progress from mild Alzheimers disease to moderate disease and, accordingly, become ineligible for these treatments.

DentaQuest Statement on New Federal Report: Inclusion of Adult Dental Benefits for People with Intellectual and Developmental Disabilities Saves States Money

Retrieved on: 
Tuesday, March 29, 2022
Dentistry, Health equity, LinkedIn, Disability in Canada, Medicare Advantage, Dental care, Intellectual, Legislation, Overalls, Adult, Research, Fiscal, CEO, Pain, National Commission, Quality of life, Health, Chronic pain, Diabetes, Twitter, NCD, CHIP, GLOBE, Medicare, Policy, Instagram, Patient, Disease, Federation, Health insurance, Medicaid, Facebook

A number of states currently provide an emergency-only dental benefit to adults with I/DD, while several others provide no dental benefits at all.

Key Points: 
  • A number of states currently provide an emergency-only dental benefit to adults with I/DD, while several others provide no dental benefits at all.
  • Other states, like Texas and Louisiana, are highlighted in the report as examples of how states can expand dental coverage to Medicaid members with I/DD.
  • Texas is used as one example, as it provides enhanced dental benefits for people with I/DD through several waiver programs.
  • And Virginia is coming up on a year this summer with enhanced dental benefits for adults enrolled in Medicaid.

Soleo Health Urges US Department of Health & Human Services to Provide Patients Access to Monoclonal Antibodies for Treatment of Alzheimer’s Disease

Retrieved on: 
Wednesday, March 16, 2022
White House, Federal Government, Other Health, Public Policy, Government, Radiology, Other Science, Software, Pharmaceutical, Research, Oncology, Medical Devices, Healthcare Reform, Infectious Diseases, Hospitals, Technology, Clinical Trials, Cardiology, Science, Biotechnology, Practice Management, Insurance, Nursing, Managed Care, Medical Supplies, General Health, Health, Diabetes, Professional Services, National coverage determination, Association, Center, Twitter, Joint Commission, Quality of life, Solution, Ageing, Dementia, Facebook, Patient, Therapy, FDA, Pharmacy, National Institute on Aging, COVID-19, Food and Drug Administration, Amyloid, Health, NCD, Centers for Medicare & Medicaid Services, National Institute, Pharmacist, Company, Population, URAC, Center for Medicare and Medicaid Innovation, Death, Human services, Distinction, CMS, LinkedIn, ACHC, Hospital, Pharmaceutical industry

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it is urging Centers for Medicare & Medicaid Services (CMS), US Department of Health & Human Services to allow patient access to monoclonal antibodies directed against Amyloid for the treatment of Alzheimers Disease.

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it is urging Centers for Medicare & Medicaid Services (CMS), US Department of Health & Human Services to allow patient access to monoclonal antibodies directed against Amyloid for the treatment of Alzheimers Disease.
  • The proposed National Coverage Determination (NCD) by CMS will unnecessarily limit patient access to important treatment advancements for this devastating disease.
  • Soleo Health also expressed its opposition to the proposed NCDs requirement that designates CMS-approved clinical trials be limited to hospital-based outpatient facilities.
  • Patient access to innovative therapy treatments is critical to supporting our aging population, including the recent FDA-approved monoclonal antibody treatment for Alzheimers patients.

NCD report finds a return on investment for offering Medicaid dental care for adults with I/DD

Retrieved on: 
Wednesday, March 9, 2022
People, Health equity, Centers for Medicare & Medicaid Services, Disability in Canada, Congress, Research, Employment, Dentistry, NCD, Education, Office of Inspector General, U.S. Department of Health and Human Services, Conditional sentence, Lung cancer, ROI, Dementia, Dental care, Administration for Community Living, Oral hygiene, Policy, Xestia castanea, Diabetes, Patient, Community Living Assistance Services and Supports Act, DD, Intellectual, Human services, Medicare, Transport, Administration, Cardiovascular disease, Caregiver, Student, Disability, Adult, Center, Health insurance, Pharmaceutical industry, Medicaid

This report was motivated by a central research question: should the Centers for Medicare and Medicaid Services require all state Medicaid agencies to implement Medicaid reimbursement and payment policies that promote access to dental care for adults with I/DD.

Key Points: 
  • This report was motivated by a central research question: should the Centers for Medicare and Medicaid Services require all state Medicaid agencies to implement Medicaid reimbursement and payment policies that promote access to dental care for adults with I/DD.
  • Medicaid adult dental benefits vary widely by state and limited research exists on how the Medicaid program should best address oral health disparities for adults with I/DD.
  • The relationship between states Medicaid dental benefits and the receipt of basic dental care among adults with I/DD;
    The relationship between state waiver and receipt of dental care;
    Estimated cost and potential savings of implementing basic dental Medicaid benefits in states that do not currently offer it;
    How coordination between DD and Medicaid agencies can improve access to dental care; and
    Promising Medicaid-funded state and private strategies for expanding dental care for adults with I/DD.
  • Adults with I/DD in those states often foregoing preventative and routine dental care and seeking emergency dental care at much higher cost, and/or developing chronic health conditions.

South African Non-Communicable Diseases Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Health, Other Health, Cerebrovascular disease, Degenerative disease, Diabetes, Research, Rheumatoid arthritis, Prevalence, Death, Cardiovascular disease, Disease, Life expectancy, Blaenavon Industrial Landscape, Fertility, COVID-19, Parkinson's disease, Non-communicable disease, NCD, Mortality, Global health, Alzheimer's disease, Pharmaceutical industry, Hyperlipidemia, Hypertension, Cancer, Cancer, African

The "South African Non-Communicable Diseases (NCD) Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "South African Non-Communicable Diseases (NCD) Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a dynamic synthesis of medical research, examining global and South African prevalence, current treatment, new medical research and advancements for these major NCDs: Cardiovascular Diseases, Hyperlipidemia, Hypertension, Cerebrovascular Diseases, Diabetes Mellitus, Cancer, Rheumatoid Arthritis, Alzheimer's Disease, Parkinson's Disease.
  • The South African Non-Communicable Diseases Industry Landscape Report 2021 provides a holistic overview of the global and South African market and will help answer the following questions:
    What are the global and South African health indicators?
  • This report covers the following categories:
    The Non-Communicable Diseases report provides insights and advancements into Cardiovascular Diseases, Hyperlipidemia, Hypertension, Cerebrovascular Diseases, Diabetes Mellitus, Cancer, Rheumatoid Arthritis, Alzheimer's Disease, and Parkinson's Disease.

NCD announces policymaker blueprint for health equity for people with disabilities

Retrieved on: 
Monday, February 14, 2022
Priority, Disability discrimination act, Disability, Solution, National Council, Congress, National Council on Disability, Council, Â, Policy, Employment, COVID-19, NCD, Health equity, GLOBE, EST, Population, Health insurance, Medicine

NCDs Health Equity Framework provides a roadmap for fixing systemic barriers within our healthcare system and references many examples of the well-documented health disparities and inequities that demand action for over 61 million people with disabilities.

Key Points: 
  • NCDs Health Equity Framework provides a roadmap for fixing systemic barriers within our healthcare system and references many examples of the well-documented health disparities and inequities that demand action for over 61 million people with disabilities.
  • In February 2021, NCD Chairman Andrs Gallegos released his Vision and Priority Statement , setting the Councils focus during his tenure on health equity as the predicate to people with disabilities being able to live, learn, and earn on an equal basis.
  • Over the last year, NCD engaged with stakeholders, policymakers, and a "dream team" of experts who have dedicated their careers to researching and addressing the health disparities of people with disabilities.
  • "Getting the health care piece right for people with disabilities is the gateway for progress in other areas like employment," said Council Member Neil Romano.

UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents

Retrieved on: 
Wednesday, February 2, 2022
CEO, Private Securities Litigation Reform Act, Government, View, Patient, Overalls, NCD, Mortality, Global Burden of Disease Study, Degenerative disease, LLY, Sickle cell disease, Non-communicable disease, Death, Form, UNICEF, Cardiovascular disease, Asthma, Primary health care, Cancer, Disease, Private sector, U.S. Fund for UNICEF, Child, Risk, Health, Geography, Education, Investment, SDG3, Form 10-K, NYSE, Multimedia, Sustainable Development Goals, U.S. Securities and Exchange Commission, Pharmaceutical industry, Cryptocurrency, Lilly

NEW YORKand INDIANAPOLIS, Feb. 2, 2022 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced anew collaboration tohelp improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 2025.

Key Points: 
  • NEW YORKand INDIANAPOLIS, Feb. 2, 2022 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced anew collaboration tohelp improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 2025.
  • Non-communicable diseases undermine a child's right to health, nutrition, education and play," said Karin Hulshof, Deputy Executive Director, UNICEF.
  • "We are grateful to Lilly for this collaboration to help strengthen health care systems children rely on and ensure health care workers are well-equipped and confident in providing care and treatment to children living with chronic conditions."
  • 1Donations from Lilly will go directly to the U.S. Fund for UNICEF, the tax-exempt organization that supports UNICEF's global work.

Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

Retrieved on: 
Friday, January 28, 2022
NCD, CMS, Headache, Climate, Disease, Alzheimer's Disease Cooperative Study, Biotechnology, Medicare, MRI, Neuroscience, Patient, EMERGE, MMSE, Brain, ARIA, Centers for Medicare & Medicaid Services, Population, Marketing, Prague Section of IADR, Health, Research and development, ADAS, Confusion, BC Healthy Living Alliance, Swelling, Lists of diseases, Pathology, Lou Ruvo Center for Brain Health, Neurology, Clinical trial, Cleveland Clinic, Center, Clinical Dementia Rating, FDA, Magnetic resonance imaging, Mini–Mental State Examination, Dementia, Bleeding, Nobel Prize, Allergy, Cognition, Spinal muscular atrophy, National coverage determination, Eisai, Regulatory science, Science, Nausea, Dizziness, Multiple sclerosis, Pharmaceutical industry, Health insurance, Medical imaging, Biogen, Alzheimer's disease, Latinx

Biogen aims to enroll 18 percent of U.S. participants in ENVISION from Black/African American and Latinx populations.

Key Points: 
  • Biogen aims to enroll 18 percent of U.S. participants in ENVISION from Black/African American and Latinx populations.
  • Based on enrollment rates from the previous Phase 3 trials with ADUHELM, the primary completion date is expected to be approximately four years after the study begins.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • The patient's healthcare provider will do magnetic resonance imaging (MRI) scans before and during treatment with ADUHELM to check for ARIA.